Trial Profile
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND 7921) (NSC 704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC 752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Fosbretabulin (Primary) ; Bevacizumab
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 25 Jul 2020 Results of post-hoc analysis assessing improvement in median progression free survival, published in the Gynecologic Oncology.
- 31 Oct 2016 Post-hoc analysis results presented at meeting of the International Gynecologic Cancer Society, as per Mateon Therapeutics media release.
- 21 Jul 2016 Status changed from active, no longer recruiting to completed, as per Mateon Therapeutics media release.